Quote | Roivant Sciences Ltd. Warrant (NASDAQ:ROIVW)
Last: | $2.75 |
---|---|
Change Percent: | 0.0% |
Open: | $2.86 |
Close: | $2.75 |
High: | $2.9199 |
Low: | $2.75 |
Volume: | 37,827 |
Last Trade Date Time: | 09/01/2023 03:00:00 am |
News | Roivant Sciences Ltd. Warrant (NASDAQ:ROIVW)
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 million Sumitomo Pharma repurchase reduces shares outstanding by 9% In the ...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. Roivant completed the sale of Telavant to Roche for $7.1B with an additi...
Message Board Posts | Roivant Sciences Ltd. Warrant (NASDAQ:ROIVW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Warrant Company Name:
ROIVW Stock Symbol:
NASDAQ Market:
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 million Sumitomo Pharma repurchase reduces shares outstanding by 9% In the ...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. Roivant completed the sale of Telavant to Roche for $7.1B with an additi...